• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Sientra Inc. (Amendment)

    5/4/22 5:18:04 PM ET
    $SIEN
    Industrial Specialties
    Health Care
    Get the next $SIEN alert in real time by email
    SC 13D/A 1 d313696dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Sientra, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    82621J105

    (CUSIP Number)

    Robert Liptak

    Clarus Ventures, LLC

    101 Main Street, Suite 1210

    Cambridge, MA 02142

    (617) 949-2200

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 4, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 82621J105    13D    Page 2 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Clarus Lifesciences I, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


    CUSIP No. 82621J105    13D    Page 3 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Clarus Ventures I Management, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


    CUSIP No. 82621J105    13D    Page 4 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Blackstone Clarus I L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP No. 82621J105    13D    Page 5 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Blackstone Holdings II L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN


    CUSIP No. 82621J105    13D    Page 6 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Blackstone Holdings I/II GP L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP No. 82621J105    13D    Page 7 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Blackstone Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO


    CUSIP No. 82621J105    13D    Page 8 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Blackstone Group Management L.L.C.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO


    CUSIP No. 82621J105    13D    Page 9 of 14 Pages

     

      1    

      NAMES OF REPORTING PERSONS.

     

      Stephen A. Schwarzman

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

      (a)  ☐        (b)  ☒

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      2,730,765

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      2,730,765

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,730,765

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      4.4%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN


    CUSIP No. 82621J105    13D    Page 10 of 14 Pages

     

    This Amendment No. 1 (“Amendment”) to the statement on Schedule 13D amends and supplements the initial statement on Schedule 13D filed with the Securities and Exchange Commission on January 11, 2019 (as amended, the “Schedule 13D”), relating to the shares of Common Stock, par value $0.01 per share (the “Common Stock”), of Sientra, Inc. (the “Issuer”).

    Certain terms used but not defined in this Amendment have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D. This Amendment constitutes an exit filing of the Reporting Persons, in respect of the Common Stock beneficially owned by the Reporting Persons.

    Item 2. Identity and Background.

    Item 2 of the Schedule 13D is hereby amended by incorporating herein by reference the information set forth on the updated Schedule I attached hereto.

    Item 4. Purpose of Transaction

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

    Nicholas Simon, an employee of Blackstone Inc. or its affiliates, no longer serves on the board of directors of the Issuer.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

    (a) and (b). Calculations of the percentage of Common Stock beneficially owned is based upon 62,606,616 shares of Common Stock outstanding as of April 12, 2022, as reported in the Issuer’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2022.

    The aggregate number and percentage of shares of Common Stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Common Stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

    As of the date hereof, Clarus Lifesciences I, L.P. (the “Fund”) directly owns 2,730,765 shares of Common Stock. Not included on this Schedule 13D are 84,699 shares of Common Stock held by Nicholas Simon for the benefit of the Fund.

    Clarus Ventures I Management, L.P. (“Clarus GP”) is the general partner of the Fund. Blackstone Clarus I L.L.C. is the general partner of Clarus GP. The sole member of Blackstone Clarus I L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is Blackstone Inc. The sole holder of the Series II preferred stock of Blackstone Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone’s senior managing directors and controlled by its founder, Stephen A. Schwarzman.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any of the Reporting Persons (other than the Fund) is the beneficial owner of the shares of Common Stock referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, and such beneficial ownership is expressly disclaimed (other than by the Fund). The filing of this statement should not be construed to be an admission that any member of the Reporting Persons are members of a “group” for the purposes of Sections 13(d) and 13(g) of the Exchange Act.


    (c) None of the Reporting Persons has effected any transaction in the Common Stock during the past 60 days.

    (d) To the best knowledge of the Reporting Persons, no person other than the Reporting Persons, or the partners, members, affiliates or shareholders of the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities beneficially owned by the Reporting Persons identified in this Item 5.

    (e) The Reporting Persons no longer beneficially own more than five percent of the Common Stock.


    SIGNATURE

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: May 4, 2022

     

    CLARUS LIFESCIENCES I, L.P.
    By: Clarus Ventures I Management, L.P., its general partner
    By: Blackstone Clarus I L.L.C., its general partner
    By:   /s/ Omar Rehman
    Name:   Omar Rehman
    Title:   Chief Compliance Officer and Secretary

     

    CLARUS VENTURES I MANAGEMENT, L.P.
    By: Blackstone Clarus I L.L.C., its general partner
    By:   /s/ Omar Rehman
    Name:   Omar Rehman
    Title:   Chief Compliance Officer and Secretary

     

    BLACKSTONE CLARUS I L.L.C.
    By:   /s/ Omar Rehman
    Name:   Omar Rehman
    Title:   Chief Compliance Officer and Secretary

     

    BLACKSTONE HOLDINGS II L.P.
    By: Blackstone Holdings I/II GP L.L.C., its general partner
    By:   /s/ Tabea Hsi
    Name:   Tabea Hsi
    Title:   Senior Managing Director

     

    BLACKSTONE HOLDINGS I/II GP L.L.C.
    By:   /s/ Tabea Hsi
    Name:   Tabea Hsi
    Title:   Senior Managing Director


    BLACKSTONE INC.

    By: Blackstone Group Management L.L.C.,

    its general partner

    By:

     

    /s/ Tabea Hsi

    Name:

     

    Tabea Hsi

    Title:

     

    Senior Managing Director

     

    BLACKSTONE GROUP MANAGEMENT L.L.C.
    By:   /s/ Tabea Hsi
    Name:   Tabea Hsi
    Title:   Senior Managing Director

     

    /s/ Stephen A. Schwarzman

    Stephen A. Schwarzman


    SCHEDULE I

    Executive Officers and Directors of Blackstone Inc.

    The name and principal occupation of each director and executive officer of Blackstone Inc. are set forth below. The address for each person listed below is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154. All executive officers and directors listed are United States citizens other than The Right Honourable Brian Mulroney, who is a citizen of Canada, and Sir John Antony Hood, who is a citizen of New Zealand.

    OFFICERS:

     

    Name   

    Present Principal Occupation or Employment

    Stephen A. Schwarzman    Founder, Chairman and Chief Executive Officer of Blackstone Inc.
    Jonathan D. Gray    President, Chief Operating Officer of Blackstone Inc.
    Michael S. Chae    Chief Financial Officer of Blackstone Inc.
    John G. Finley    Chief Legal Officer of Blackstone Inc.

    DIRECTORS:

     

    Name   

    Present Principal Occupation or Employment

    Stephen A. Schwarzman    Founder, Chairman and Chief Executive Officer of Blackstone Inc.
    Jonathan D. Gray    President, Chief Operating Officer of Blackstone Inc.
    Kelly A. Ayotte    Former United States Senator from New Hampshire
    Joseph P. Baratta    Global Head of Private Equity at Blackstone Inc.
    James W. Breyer    Founder and Chief Executive Officer of Breyer Capital
    Reginald J. Brown    Partner for the law firm, Kirkland & Ellis
    Sir John Antony Hood    Former President and Chief Executive Officer of the Robertson Foundation and Former Chair of the Rhodes Trust
    Rochelle B. Lazarus    Chairman Emeritus & Former Chief Executive Officer, Ogilvy & Mather Worldwide
    Jay O. Light    Dean Emeritus, Harvard Business School
    The Right Honourable Brian Mulroney    Senior Partner for the Montreal law firm, Norton Rose Fulbright Canada LLP
    William G. Parrett    Retired CEO of Deloitte Touche Tohmatsu and retired Senior Partner of Deloitte (USA)
    Ruth Porat    Chief Financial Officer of Alphabet Inc. and Google Inc.
    Get the next $SIEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIEN

    DatePrice TargetRatingAnalyst
    4/14/2022$8.00Buy
    Lake Street
    More analyst ratings

    $SIEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sientra Inc. (Amendment)

      SC 13G/A - Sientra, Inc. (0001551693) (Subject)

      2/20/24 1:38:37 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/6/24 10:00:53 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/15/23 3:19:14 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Financials

    Live finance-specific insights

    See more
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook

      IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru

      10/30/23 5:00:51 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Record Second Quarter Financial and Operational Results

      Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha

      8/10/23 4:03:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Menezes Ronald covered exercise/tax liability with 3,625 shares, decreasing direct ownership by 18% to 16,775 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:38 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Van Hove Caroline F. covered exercise/tax liability with 741 shares, decreasing direct ownership by 8% to 8,239 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:11 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form 4: Bennett Oliver Christian was granted 2,739 shares, increasing direct ownership by 13% to 23,100 units

      4 - Sientra, Inc. (0001551693) (Issuer)

      9/11/23 9:05:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    SEC Filings

    See more
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/16/24 4:15:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/13/24 9:00:40 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      1/29/24 6:07:11 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

      Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid

      4/2/24 6:30:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

      IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d

      2/13/24 8:30:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Sientra with a new price target

      Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00

      4/14/22 9:15:44 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Canaccord Genuity reiterated coverage on Sientra with a new price target

      Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      5/12/21 11:21:33 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SVB Leerink reiterated coverage on Sientra with a new price target

      SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

      5/12/21 7:20:27 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

      IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional

      6/20/23 8:35:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors

      SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one

      7/19/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Announces Appointment of Chief Financial Officer

      SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of

      7/12/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care